Predictive factors for early super response to bimekizumab in psoriasis: A real-world study

During the 2025 European Academy of Dermatology and Venereology (EADV) Congress, September 17–20, 2025, Paris, FR, Tubanur Cetinarslan presented results from a real-world study exploring predictive factors for early super response (ESR) to bimekizumab in 341 adult patients with moderate-to-severe psoriasis. Most patients were diagnosed with plaque psoriasis (93%). Eligible patients received bimekizumab for at least 12 weeks. Outcomes included the Psoriasis Area and Severity Index (PASI), Physician Global Assessment (PGA), and adverse events (AEs). 

Key data: At Week 24, 97.3%, 93.9%, and 17.6% of patients achieved PASI 75, PASI 90, and PASI 100 with bimekizumab. Multivariate analysis (MVA) indicated that positive family history (p = 0.041), palmoplantar involvement (p = 0.008), and elevated baseline PASI scores (p < 0.001) were associated with reduced likelihood of achieving an ESR. MVA also showed that psoriatic arthritis and cardiovascular disease were predictive of AEs (p = 0.047 and p = 0.038, respectively). The overall frequency of AEs was 20.5%; the most common AE was candidiasis (13.7%).

Key learning: This real-world study identified several predictive factors for ESR to bimekizumab in adult patients with psoriasis. Further research is warranted on the long-term safety and efficacy of bimekizumab.